What is APRE stock price today?

APRE (Aprea Therapeutics Inc) stock is trading at $0.76 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is APRE stock going up or down today?

APRE stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy APRE stock now?

The decision to buy APRE depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is APRE a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for APRE based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is APRE stock overvalued or undervalued?

Use our DCF valuation calculator to determine if APRE is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is APRE's P/E ratio?

P/E ratio data for APRE will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is APRE's market cap?

APRE (Aprea Therapeutics Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is APRE's price to book ratio?

APRE trades at a price-to-book (P/B) ratio of 0.24, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does APRE pay dividends?

APRE does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is APRE's dividend yield?

APRE does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is APRE stock a good long-term investment?

APRE's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is APRE's revenue growth rate?

APRE has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for APRE are available on our dashboard with complete income statement analysis.

What are the risks of investing in APRE?

Key risks for APRE include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does APRE compare to its competitors?

Compare APRE to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize APRE's performance and positioning.

What is APRE's stock price target for 2026?

Our AI model provides price targets for APRE based on fundamental analysis: Bull case $0.99 (+30%), Base case $0.88 (+15%), Bear case $0.69 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about APRE?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for APRE. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is APRE's next earnings report?

APRE reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

APRE - Aprea Therapeutics Inc

NYSE * Healthcare * Biotechnology

$0.76

$-0.01 (-1.35%)

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Price Chart

Loading chart...

APRE Key Statistics

Market Cap

$9.47M

P/B Ratio

0.24

EPS

$-1.49

Revenue Growth

-1.0%

Employees

How APRE Compares to Peers

APRE is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
APRE(This stock)	$9.47M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$186.52B	24.0	0%	0.2%	vs AMGN
GILDGilead Sciences	$160.39B	17.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.12B	26.2	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.89B	15.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$29.00B	21.1	0%	0.1%	vs BIIB

Aprea Therapeutics Inc Company Information

Headquarters: 3805 Old Easton Road, Doylestown, PA, United States, 18902, undefined
Website: aprea.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: June 5, 2026 at 11:51 AM EDT

Ready to invest in APRE?

Commission-free trading available. Affiliate links.

APRE Lician Score

5% confidence

4.0/10

Neutral

APRE has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates APREacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

APRE Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for APRE

Dashboard

Enter a ticker to analyze